1.
COVID-19 clinical trials: learning from exceptions in the research chaos
by Tikkinen, Kari A O
Nature medicine, 2020-11, Vol.26 (11), p.1671-1672
2.
Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0
by Boers, Maarten
Journal of clinical epidemiology, 2014, Vol.67 (7), p.745-753
3.
Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands
by van den Bogert, Cornelis A
Journal of clinical epidemiology, 2017, Vol.88, p.140-147
4.
Randomised clinical trial: low‐FODMAP rye bread vs. regular rye bread to relieve the symptoms of irritable bowel syndrome
by Laatikainen, R.
Alimentary pharmacology & therapeutics, 2016-09, Vol.44 (5), p.460-470
6.
Exploring the ethical and regulatory issues in pragmatic clinical trials
by Califf, Robert M
Clinical trials (London, England), 2015-10, Vol.12 (5), p.436-441
7.
A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines
by Dal-Ré, Rafael
Journal of clinical epidemiology, 2019-10, Vol.114, p.60-71
8.
The global landscape of stem cell clinical trials
by Li, Matthew D
Regenerative medicine, 2014-01-01, Vol.9 (1), p.27-39
9.
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
by Cruz Rivera, Samantha
Nature medicine, 2020-09, Vol.26 (9), p.1351-1363
10.
Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials
by Carlisle, Benjamin
Clinical trials (London, England), 2015-02, Vol.12 (1), p.77-83
11.
SPIRIT 2013: new guidance for content of clinical trial protocols
by Chan, An-Wen
The Lancet (British edition), 2013, Vol.381 (9861), p.91-92
12.
Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
by Ashida, K.
Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (2), p.240-251
13.
RIKEN suspends first clinical trial involving induced pluripotent stem cells
by Garber, Ken
Nature biotechnology, 2015-09, Vol.33 (9), p.890-891
14.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
by Drilon, Alexander
The lancet oncology, 2020-02, Vol.21 (2), p.261-270
15.
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
by FELSON, David T
Annals of the rheumatic diseases, 2011, Vol.70 (3), p.404-413
16.
Independent data monitoring committees: Preparing a path for the future
by Hess, Connie N., MD, MHS
The American heart journal, 2014, Vol.168 (2), p.135-141.e1
17.
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-...
by Gupta, Ajay, MRCP
The Lancet (British edition), 2017, Vol.389 (10088), p.2473-2481
18.
Examining and Enabling the Role of Health Care Providers as Patient Engagement Facilitators in Clinical Trials
by Getz, Kenneth A
Clinical therapeutics, 2017-11, Vol.39 (11), p.2203-2213
19.
Industry funding was associated with increased use of core outcome sets
by Kirkham, Jamie J
Journal of clinical epidemiology, 2019, Vol.115, p.90-97
20.
Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study
by van den Bogert, Cornelis A
Journal of clinical epidemiology, 2017-09, Vol.89, p.199-208
Filter electronic articles 41.689 Hits
Remove Filters
- Subjects
- Science & Technology
- Life Sciences & Biomedicine (40.916)
- Humans (36.881)
- more ...